Fifty percent of dapirolizumab pegol-treated patients in the Phase 3 PHOENYCS GO trial achieved a BICLA response at Week 48 — a result now getting a second look at EULAR 2026, where UCB and Biogen are pressing a more clinically uncomfortable argument: that hitting a composite disease-activity endpoint means little if patients are still accumulating steroid toxicity to get there. The new post hoc analyses shift the conversation from whether the drug works to whether it works without the collateral damage that defines SLE management for most patients.
The EULAR data zeroes in on patients entering PHOENYCS GO with glucocorticoid doses above 7.5 mg/day prednisone equivalent — a threshold that carries real clinical weight, since chronic exposure above that level is linked to organ damage accrual over time. In that subgroup, a higher proportion of patients on dapirolizumab pegol plus standard of care managed to taper to ≤7.5 mg/day while simultaneously achieving BICLA response, SRI-4 response, or remaining free from moderate-to-severe BILAG-2004 flares through Week 48, compared with placebo plus standard of care. Layered on top of this are immunological marker improvements — rising C3 and C4 complement levels, declining anti-dsDNA antibodies in those with abnormal baseline values — and reduced flare rates under alternative flare definitions designed to capture events that standard instruments miss. That last point matters: if the field’s measurement tools are insensitive to moderate flares, approved comparators and investigational agents alike are being judged on a blunted scale.
The SLE biologics market is projected at $3.71 billion in 2026, with belimumab approved since 2011 and anifrolumab approved in 2021, meaning dapirolizumab pegol enters a market with established biologics rather than a vacuum. Its differentiation case rests on mechanism — CD40L inhibition disrupting B-cell activation, type 1 interferon secretion, and T-cell co-stimulation simultaneously — and on the steroid-sparing signal, which neither of the existing agents has made a primary commercial argument. UCB and Biogen are essentially betting that regulators and payers will weight glucocorticoid tapering as a co-equal outcome to disease-activity response, not a secondary nice-to-have.
The data presented are post hoc and not powered for the steroid-tapering analyses, which means the confirmatory burden remains. Watch the Lancet-published primary results and any forthcoming regulatory submission language closely — if UCB and Biogen can formalize steroid reduction as a labeled claim rather than a supportive endpoint, that reshapes how physicians justify switching patients from existing biologics.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
